Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 22, Issue 2, 2017, Pages 99-104

  McLain, Julian Hardy ^a   Alsterda, Andrew Jacob ^a   Arora, Rohit R ^b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b Captain James A Lovell Federal Health Care Center   (United States)

Author keywords

atherosclerosis; cardiovascular disease; hypercholesterolemia

Indexed keywords

ALDOSTERONE; ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLACEBO; TORCETRAPIB; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BURNING SENSATION; CHOLESTEROL ESTER TRANSFER PROTEIN GENE; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ELEVATED BLOOD PRESSURE; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; NONHUMAN; PATIENT COMPLIANCE; SIDE EFFECT;

EID: 85011344662     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248416662349     Document Type: Article

References (49)

1. Barkowski RS, Frishman WH,. HDL metabolism and CETP inhibition. Cardiol Rev. 2008; 16 (3): 154-162.
2. Fielding CJ, Havel RJ,. Cholesteryl ester transfer protein: friend or foe? J Clin Invest. 1996; 97 (12): 2687-2688.
3. Sviridov D,. High-density lipoprotein-a hero, a mirage, or a witness? Front Cardiovasc Med. 2014; 1: 9.
4. Fielding CJ, Fielding PE,. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995; 36 (2): 211-228.
5. Lewis GF, Rader DJ,. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005; 96 (12): 1221-1232.
6. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79 (1): 8-15.
7. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361 (9364): 1149-1158.
8. Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350 (15): 1495-1504.
9. Boden WE,. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000; 86 (12A): 19L-22L.
10. Di angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302 (18): 1993-2000.
11. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317 (20): 1237-1245.
12. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341 (6): 410-418.
13. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365 (24): 2255-2267.
14. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371 (3): 203-212.
15. Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016; 351 (6278): 1166-1171.
16. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014; 371 (25): 2383-2393.
17. Cappel DA, Palmisano BT, Emfinger CH, Martinez MN, Mcguinness OP, Stafford JM,. Cholesteryl ester transfer protein protects against insulin resistance in obese female mice. Mol Metab. 2013; 2 (4): 457-467.
18. Plump AS, Masucci-magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR,. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999; 19 (4): 1105-1110.
19. Bonora M, Wieckowsk MR, Chinopoulos C, et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene. 2015; 34 (12): 1608.
20. Agellon LB, Walsh A, Hayek T, et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem. 1991; 266 (17): 10796-1801.
21. Marotti KR, Castle CK, Murray RW, Rehberg EF, Polites HG, Melchior GW, The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice. Arterioscler Thromb. 1992; 12 (6): 736-744.
22. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000; 20 (9): 2106-2112.
23. Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 1985; 58 (1-3): 175-186.
24. Inazu A, Jiang XC, Haraki T, et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest. 1994; 94 (5): 1872-1882.
25. Sakai N, Santamarina-fojo S, Yamashita S, Matsuzawa Y, Brewer HB,. Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice site selection. J Lipid Res. 1996; 37 (10): 2065-2073.
26. Gotoda T, Kinoshita M, Shimano H, et al. Cholesteryl ester transfer protein deficiency caused by a nonsense mutation detected in the patient's macrophage mRNA. Biochem Biophys Res Commun. 1993; 194 (1): 519-524.
27. Arai T, Yamashita S, Sakai N, et al. A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. J Lipid Res. 1996; 37 (10): 2145-2154.
28. Hirano K, Yamashita S, Kuga Y, et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol. 1995; 15 (11): 1849-1856.
29. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990; 323 (18): 1234-1238.
30. Wang J, Wang LJ, Zhong Y, et al. CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population. Lipids Health Dis. 2013; 12: 176.
31. Hassan M., HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack. Glob Cardiol Sci Pract. 2014; 2014 (3): 235-240.
32. Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004; 45 (5): 948-953.
33. Thompson A, Di angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008; 299 (23): 2777-2788.
34. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996; 97 (12): 2917-2923.
35. Johannsen TH, Frikke-schmidt R, Schou J, Nordestgaard BG, Tybjærg-hansen A,. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012; 60 (20): 2041-2048.
36. Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab. 2006; 91 (9): 3382-3388.
37. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357 (21): 2109-2122.
38. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008; 154 (7): 1465-1473.
39. Tardif JC, Rhéaume E, Lemieux perreault LP, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015; 8 (2): 372-382.
40. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (d al-PLAQUE): a randomized clinical trial. Lancet. 2011; 378 (9802): 1547-1559.
41. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367 (22): 2089-2099.
42. Teramoto T, Takeuchi M, Morisaki Y, Ruotolo G, Krueger KA,. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. Am J Cardiol. 2014; 113 (12): 2021-2029.
43. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011; 306 (19): 2099-2109.
44. Nicholls SJ, Lincoff A, Barter P, et al. Late-Breaking Clinical Trials II. The ACCELERATE trial: impact of the cholesteryl ester transfer protein inhibitor evacetrapib on cardiovascular outcome. Paper presented at: 65th Annual Scientific Session and Expo of the American College of Cardiology; April 2-4, 2016; Chicago, IL.
45. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010; 363 (25): 2406-2415.
46. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009; 157 (2): 352-360. e2.
47. Gotto AM, Cannon CP, Li XS, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014; 113 (1): 76-83.
48. Davidson M, Liu SX, Barter P, et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013; 54 (2): 467-472.
49. Kastelein JJ, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015; 385 (9983): 2153-2161.